Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.47 |
| ▸ | HSD11B1 | P28845 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13278551 | 0.88 | OPRM1 (0.50) | SMN1; SMN2HSD17B10HSD11B1ALDH1A1KDM4E | |
| SCHEMBL14074880 | 0.82 | HSD11B1 (0.48) | SMN1; SMN2HSD11B1ALDH1A1KDM4EMEN1 | |
| SCHEMBL13278723 | 0.80 | SMN1; SMN2 (0.51) | SMN1; SMN2HSD17B10ALDH1A1MEN1KMT2A | |
| SCHEMBL7240654 | 0.77 | SMN1; SMN2 (0.46) | SMN1; SMN2ALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL3718479 | 0.77 | KDM4E (0.64) | SMN1; SMN2ALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL18347395 | 0.76 | SMN1; SMN2 (0.47) | SMN1; SMN2ALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL14074888 | 0.75 | HSD11B1 (0.49) | HSD11B1ALDH1A1KDM4EPOLBLMNA | |
| SCHEMBL6627628 | 0.74 | KDM4E (0.64) | SMN1; SMN2ALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL18347410 | 0.73 | SMN1; SMN2 (0.47) | SMN1; SMN2ALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL14074899 | 0.72 | KDM4E (0.62) | SMN1; SMN2ALDH1A1KDM4EMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7514462-B2 | ω-Cycloalkyl 17-heteroaryl prostaglandin E2 analogs as EP2-receptor agonists | ALLERGAN, INC. (US) | 2009-04-07 | — | — | US | disclosed |
| US-20070219262-A1 | omega-Cycloalkyl 17-Heteroaryl Prostaglandin E2 Analogs as EP2-Receptor Agonists | ALLERGAN, INC. | 2007-09-20 | — | — | US | disclosed |
| US-7223746-B2 | Omega cycloalkyl 17-heteroaryl prostaglandin E2 analogs as EP2-receptor agonists | ALLERGAN, INC. (US) | 2007-05-29 | — | — | US | disclosed |
| US-7022726-B2 | ω-cycloalkyl 17-heteroaryl prostaglandin E2 analogs as EP2-receptor agonists | ALLERGAN, INC. (US) | 2006-04-04 | — | — | US | disclosed |
| EP-1442033-B1 | OMEGA-CYCLOALKYL 17-HETEROARYL PROSTAGLANDIN E2 ANALOGS AS EP2-RECEPTOR AGONISTS | ALLERGAN INC (US) | 2005-09-28 | — | — | EP | disclosed |
| US-20050113338-A1 | Cycloalkyl 17-heteroaryl prostaglandin E2 analogs as EP2-receptor agonists | ALLERGAN, INC. | 2005-05-26 | — | — | US | disclosed |
| EP-1438104-A1 | CO-CYCLOALKYL 17-HETEROARYL PROSTAGLANDIN E2 ANALOGS AS EP2-RECEPTOR AGONISTS | Allergan, Inc. (US) | 2004-07-21 | — | — | EP | disclosed |
| US-20040106580-A1 | Omega-cycloalkyl 17-heteroaryl prostaglandin E2 analogs as EP2-receptor agonists | ALLERGAN INC. | 2004-06-03 | — | — | US | disclosed |
| US-6710072-B2 | VISION DEFECTS | ALLERGAN, INC. | 2004-03-23 | — | — | US | disclosed |
| US-20030130239-A1 | Omega-cycloalkyl 17-heteroaryl prostaglandin E2 analogs as EP2-receptor agonists | ALLERGAN, INC. | 2003-07-10 | — | — | US | disclosed |
| US-6586462-B2 | ω-Cycloalkyl 17-heteroaryl prostaglandin E2 analogs as EP2-receptor agonists | ALLERGAN, INC. | 2003-07-01 | — | — | US | disclosed |
| WO-2003037433-A1 | CO-CYCLOALKYL 17-HETEROARYL PROSTAGLANDIN E2 ANALOGS AS EP2-RECEPTOR AGONISTS | ALLERGAN, INC. (US) | 2003-05-08 | — | — | WO | disclosed |
| US-20020187961-A1 | Omega-cycloalkyl 17-heteroaryl prostaglandin E2 analogs as EP2-receptor agonists | ALLERGAN, INC. | 2002-12-12 | — | — | US | disclosed |
| US-6376533-B1 | VISION DEFECTS | ALLERGAN SALES, INC. | 2002-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030130239-A1 | Omega-cycloalkyl 17-heteroaryl prostaglandin E2 analogs as EP2-receptor agonists | PTGER2, PTGER4, PTGER1 | SMN1; SMN2 4532/4885HSD17B10 436/4885HSD11B1 390/4885 |
| US-20020187961-A1 | Omega-cycloalkyl 17-heteroaryl prostaglandin E2 analogs as EP2-receptor agonists | PTGER2, PTGER1, PTGER3 | SMN1; SMN2 4248/4885HSD17B10 548/4885HSD11B1 337/4885 |
| US-20070219262-A1 | omega-Cycloalkyl 17-Heteroaryl Prostaglandin E2 Analogs as EP2-Receptor Agonists | PTGER4, PTGER2, LTB4R2 | SMN1; SMN2 4651/4885HSD17B10 585/4885HSD11B1 355/4885 |
| US-20050113338-A1 | Cycloalkyl 17-heteroaryl prostaglandin E2 analogs as EP2-receptor agonists | PTGER4, PTGER2, LTB4R2 | SMN1; SMN2 4796/4885HSD17B10 502/4885HSD11B1 321/4885 |
| US-20040106580-A1 | Omega-cycloalkyl 17-heteroaryl prostaglandin E2 analogs as EP2-receptor agonists | PTGER2, PTGER4, PTGER1 | SMN1; SMN2 4550/4885HSD17B10 450/4885HSD11B1 391/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.